Longevity Health Holdings Enters into Securities Purchase Agreement for Up to $625,000 in Gross Proceeds
Longevity Health Holdings (XAGE) entered a Securities Purchase Agreement with Puritan Partners LLC for up to $625,000 in 10% senior secured convertible notes.
Rhea-AI Summary
Longevity Health Holdings (XAGE) entered a Securities Purchase Agreement with Puritan Partners LLC for up to $625,000 in 10% senior secured convertible notes.
At the initial closing on August 31, 2026, Longevity received $375,000 in gross proceeds, before fees and expenses, via a note with a 10% original issue discount and an original principal amount of $416,666.67, maturing on February 29, 2028. The note bears 10% annual interest and is convertible into common stock at $0.50 per share, subject to adjustment, and is secured by substantially all assets of the company and its subsidiaries.
The agreement allows for two additional notes, each providing $125,000 in gross proceeds on substantially the same terms, for up to $277,778 in additional aggregate principal. The second tranche depends on the effectiveness of a resale registration statement for the underlying shares, while the third tranche is at Puritan’s sole discretion.
Positive
- $375,000 initial gross proceeds received on August 31, 2026
- Facility permits up to $625,000 in aggregate gross proceeds
- Convertible note carries 10% annual interest with maturity in 2028
- Two potential additional tranches of $125,000 each available
Negative
- Notes are senior secured by substantially all company and subsidiary assets
- Convertible at $0.50 per share, which may lead to share issuance upon conversion
- Notes issued with a 10% original issue discount, increasing effective financing cost
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company draws initial
PITTSBURGH, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (OTCQB: XAGE) (“Longevity” or the “Company”) today announced that it has entered into a Securities Purchase Agreement with Puritan Partners LLC (“Puritan”) providing for up to
“We’re pleased to deepen our relationship with Puritan Partners through this new facility, which gives Longevity additional financial flexibility as we continue to build out our regenerative bio-aesthetics platform and pursue other strategic opportunities,” said Janakiram Ajjarapu, Chairman and Chief Executive Officer of the Company. “The agreement with Puritan gives us room to draw additional capital as we achieve key milestones.”
At the initial closing on August 31, 2026, the Company received initial gross proceeds of
The Purchase Agreement provides for the potential issuance to Puritan of two additional notes, each for
Additional information regarding the terms of the Note and related transaction documents is included in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 4, 2026.
About Longevity Health Holdings, Inc.
Longevity Health Holdings, Inc. is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics. The Company develops, manufactures, and markets cosmetic skincare and haircare products designed to help people look and feel their best at any age. The Company is headquartered in Pittsburgh, Pennsylvania. For more information, visit www.healthxage.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits of the Purchase Agreement, the Company’s plans to pursue additional financing, and the Company’s future business and financial condition. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that anticipated additional financing is not completed on the terms described or at all, risks relating to the Company’s obligations under the Purchase Agreement and the related financing instruments, including potential dilution, security interests in substantially all Company assets and specified subsidiary assets, repayment and prepayment obligations, and default-related remedies, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements, except as required by law.
Contact
Bryan J. Cassaday
bcassaday@healthxage.com
FAQ
What are the key terms of the initial note issued to Puritan Partners?
The initial note has an original principal amount of $416,666.67, carries 10% per annum interest, is due on February 29, 2028, and was issued with a 10% original issue discount. It is convertible into Longevity common stock at a $0.50 per share conversion price, subject to adjustment, and is secured by substantially all assets of the company and its subsidiaries.
Under what conditions can Longevity access the two additional note tranches?
The Purchase Agreement contemplates two additional notes, each providing $125,000 in gross proceeds. The second tranche is subject to the effectiveness of a resale registration statement covering the underlying shares, while the third tranche is at Puritan Partners’ sole discretion.
Where can investors find more detailed information about this financing?
Additional information on the terms of the note and related transaction documents is included in Longevity Health Holdings’ Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 4, 2026.